Abstract
The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Dopaminergic Modulation of Sleep-Wake States
Volume: 16 Issue: 4
Author(s): Andrea Herrera-Solis, Wendy Herrera-Morales, Luis Nunez-Jaramillo and Oscar Arias-Carrion*
Affiliation:
- Unidad de Trastornos del Movimiento y Sueño (TMS). Hospital General Dr. Manuel Gea González, Avenida Calzada de Tlalpan 4800, Tlalpan, Sección XVI, Ciudad de México, C.P. 14080,Mexico
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Abstract: The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Export Options
About this article
Cite this article as:
Herrera-Solis Andrea, Herrera-Morales Wendy , Nunez-Jaramillo Luis and Arias-Carrion Oscar *, Dopaminergic Modulation of Sleep-Wake States, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320145429
DOI https://dx.doi.org/10.2174/1871527316666170320145429 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computational Methods Dedicated to Neurological Disorder Detection through Epistasis Analysis: A Review
Current Chinese Engineering Science Transient Disruption of Fear-Related Memory by Post-Retrieval Inactivation of Gastrin-Releasing Peptide or N-Methyl-D-Aspartate Receptors in the Hippocampus
Current Neurovascular Research Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options
Current Pharmaceutical Design Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Capturing and Amplifying Impurities from Recombinant Therapeutic Proteins Via Combinatorial Peptide Libraries: A Proteomic Approach
Current Pharmaceutical Biotechnology A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry TLR2 and TLR4 Expression During Bacterial Infections
Current Pharmaceutical Design Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery EDITORIAL (Hot Topic: Psychiatric/Psychosocial Rehabilitation (PSR))
Current Psychiatry Reviews The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Editorial - Progress of Current Alzheimer Research
Current Alzheimer Research Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders
Current Pharmaceutical Design Nucleoside Transporter Proteins
Current Vascular Pharmacology Preface
Applied Clinical Research, Clinical Trials and Regulatory Affairs Meet Our Editors
Medicinal Chemistry OCD or not OCD? A Critical Evaluation of the Obsessive Compulsive Related Disorders
Current Psychiatry Reviews Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs
Current Neuropharmacology Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets miR-132 Down-regulates Methyl CpG Binding Protein 2 (MeCP2) During Cognitive Dysfunction Following Chronic Cerebral Hypoperfusion
Current Neurovascular Research